4
2
1
↑4
↓2
—1
Evidence suggests Alcohol mayincreaseLiver fibrosis.
5 studies (7 claims)
Emerging evidence
Typical effective dose 20 (20–20) %across 1 dosed study
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| sweetening the alcohol solution with artificial sweeteners | Increases - led to | hepatic fibrosis | Animal | — | Aspartame (0.025%), saccharin (0.025%), cyclamate (0.05%) in alcohol (8% v/v) solution. | Use of artificial sweeteners to promote alcohol consumption by rats.cited 4× |
| alcohol treatment with exposure to carbon tetrachloride vapour, 40 ppm, six hours per night for five nights per week, over a period of 14 weeks | No effect - did not differ significantly among the treatments | fibrosis | Animal | rats | Aspartame (0.025%), saccharin (0.025%), cyclamate (0.05%) in alcohol (8% v/v) solution. | Use of artificial sweeteners to promote alcohol consumption by rats.cited 4× |
| alcohol treatment with exposure to carbon tetrachloride vapour, 40 ppm, six hours per night for five nights per week, over a period of 14 weeks | Increases - had | varying degrees of fibrosis | Animal | all the others | Aspartame (0.025%), saccharin (0.025%), cyclamate (0.05%) in alcohol (8% v/v) solution. | Use of artificial sweeteners to promote alcohol consumption by rats.cited 4× |
| hepatocyte specific Cebpb knockout at the time of alcohol cessation | Increases - promoted | fibrosis resolution | Animal | mice | 20% alcohol in drinking water for 20 weeks (ALD induction), followed by 4 weeks of plain water (resolution phase). | Continuous activation of C/EBPβ transcription factor prevents fibrosis resolution after alcohol cessation. |
| cholestatic liver fibrosis and subsequent alcohol exposure (DDC + EtOH) | Increases - exhibited exacerbated | liver fibrosis with a pericellular pattern | Animal | mice | Up to 24 g/kg of ethyl alcohol in a high-fat diet. | A Novel Mouse Model of Acute-on-Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis.cited 9× |
| patchouli alcohol (PA) (40, 20 mg/kg) | Decreases - suppressed | activation of pro-fibrosis cytokines including TGF-β1 in kidney | Animal | spontaneously hypertensive rats (SHR) | — | Patchouli alcohol against renal fibrosis of spontaneously hypertensive rats via Ras/Raf-1/ERK1/2 signalling pathway.cited 3× |
| Patchouli alcohol (PatA) treatment | Decreases - controlling | myocardial fibrosis | AnimalMolecular | diabetic mice | — | Patchouli Alcohol Protects the Heart against Diabetes-Related Cardiomyopathy through the JAK2/STAT3 Signaling Pathway.cited 3× |